PLRZ polyrizon-biotech.com: Accounting Value per Share

Polyrizon Ltd (PLRZ) revenues rely on the market launch of barrier agents, specifically Bio-Layer nasal gels. The book value per share trend demonstrates capital accumulation, where the current status is 11.55. Trap and Protect technology establishes a hygiene standard by blocking viruses. Meanwhile, the project's success is tied to biopolymer trials and stable long-term capital.

Polyrizon Ltd - PLRZ Net Assets per Share (period 10/30/2024 - 10/27/2026)

Summary analytical data breakdowns for Polyrizon Limited (PLRZ)

- price and consensus price forecast:
Price Chart Polyrizon Ltd.|PLRZ - Fair Value Consensus
- market capitalization data:
Market Valuation Polyrizon Ltd|PLRZ - Full Business Value
- book capitalization data:
Net Assets per Single Share Polyrizon|PLRZ - Book Valuation of Business|Market Value to Book Value Ratio polyrizon-biotech.com|PLRZ - Total Asset Value of Company
- debt and liquidity data:
Total Debt to Capital Polyrizon Ltd|PLRZ - Long-Term Liabilities to Capital|Short-Term Debt to Capital Polyrizon Ltd.|PLRZ - Company Total Debt|Debts to Book Capitalization Polyrizon Ltd
Analysis of all company metrics:polyrizon-biotech.com PLRZ

Polyrizon Ltd (PLRZ) leadership in developing polymer barriers for mucosal protection makes its market capitalization dependent on the value of intangible assets and patents. Analyzing the total book value, an investor can see the residual value of net assets per share, which allows for an assessment of the business's intrinsic value; however, the long-term consensus requires comparing this metric with current operating profitability.

Competitors of Polyrizon Ltd (PLRZ)

Net Assets per Single Share Vertex Pharmaceuticals Inc. (VRTX)|Alnylam Corp (ALNY) - Accounting Value of a Share|Accounting Value per Share Insmed Incorporated (INSM)|UTHR (unither.com) - Share Book Value|BMRN: Net Assets per Single Share|Net Assets per Share BBIO|BGM - Net Assets per Single Share|Share Book Value Cogent Corp (COGT)|XERS: Book Value per Share|Net Asset Value per Share kerostx.com KROS|ARCT: Book Value per Share|ETON - Accounting Value per Share|Kamada Corp - Book Value per Share|Fulcrum Corp (FULC) - Net Assets per Share|ABEO (Abeona Therapeutics, Inc.) - Book Value per Share|Book Value per Share MREO|Net Assets per Single Share Protalix BioTherapeutics, Inc. (PLX)|Net Assets per Single Share pliantrx.com (PLRX)|Book Value per Share APLT|RNTX - Net Assets per Share|Accounting Value per Share Gelteq Limited Inc|AYTU - Share Book Value|Book Value per Share CMMB|SRx Health Solutions (SRXH) - Net Asset Value per Share|Book Value per Share Aeterna Zentaris Inc (AEZS)|Equity per Share Cyclo Therapeutics, Inc (CYTH)|Inozyme Pharma, Inc. (INZY) - Accounting Value per Share|Accounting Value of a Share RPHM (reneopharma.com)|COSCIENS Biopharma (CSCI) - Net Assets per Single Share